Vertex Pharmaceuticals Investments - Gross Unrealized Losses increased by 634.2% to $3.40B in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 209.1%, from $1.10B to $3.40B.
investments_gross_unrealized_losses| Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Value | $702.70M | $2.13B | $2.28B | $4.00B | $4.60B | $443.80M | $1.10B | $816.00M | $463.10M | $3.40B |
| QoQ Change | — | +203.1% | +7.0% | +75.4% | +15.0% | -90.4% | +147.9% | -25.8% | -43.2% | +634.2% |
| YoY Change | — | — | — | +469.2% | +116.0% | -80.5% | -72.5% | -82.3% | +4.3% | +209.1% |